Skip to content

Randomised trial, 2023

Does chaste tree help treat high prolactin levels related to PMS?

Some evidence suggests chaste tree might help with mild high prolactin levels, but the evidence is weak and unclear. We need larger, better studies.

Early or limited evidence Patients with high prolactin from published studies (literature review)

What they did

A literature review analyzing published studies on chaste tree extracts and high prolactin levels. The authors examined existing research to summarize what is known about this topic.

What they found

Some evidence suggests chaste tree may help manage mild high prolactin in selected patients, but results are inconsistent across studies. No large randomized controlled trials exist. How chaste tree works is still unclear.

What it means for you

Chaste tree may be safe to try for mild high prolactin, particularly for women who prefer plant-based treatment. However, this is only a summary of existing research, not a new study, and the evidence is not strong enough yet to recommend it widely.

About the study

Original title
Vitex agnus castus effects on hyperprolactinaemia
Authors
Puglia LT, Lowry J, Tamagno G
Journal
Frontiers in endocrinology
Year
2023
Study design
Randomised trial
What was tested
Chaste tree (Vitex agnus castus) extracts
Open access
Yes
Original abstract

Background: Vitex agnus castus (VAC), also known as chaste tree, is a plant from the Mediterranean area, Crimea, and central Asia. Its fruit has been used for more than 2500 years as phytotherapic agent. In the last century, VAC has been mostly used for the treatment of premenstrual syndrome (PMS), menstrual irregularities, fertility disorders, and symptoms of menopause. Since some degree of hyperprolactinaemia may be observed in patients with such disorders, VAC effects on hyperprolactinaemia have been assessed in a small number of studies and in some patient series or single case reports. It has been postulated that the diterpenes contained in VAC extract may interact with dopamine D2 receptors (D2R) and inhibit prolactin release via dopamine D2R activation in the anterior pituitary. Most of the published papers focus on the use of VAC for the management of PMS or infertility. However, due to its action on D2R, VAC could have a role in the treatment of mild hyperprolactinaemia, including patients with idiopathic hyperprolactinaemia, microprolactinoma, drug-induced hyperprolactinaemia, or polycystic ovary syndrome. Methods: We have reviewed and analysed the data from the literature concerning the use of VAC extracts in patients with hyperprolactinaemia. Results: Some evidence suggests a possible role of VAC for the management of hyperprolactinaemia in selected patients, though in an inhomogeneous way. However, there are not any large randomized controlled trials supporting the same and the precise pharmacological aspects of VAC extract in such a clinical setting still remain obscure. Conclusion: It appears that VAC may represent a potentially useful and safe phytotherapic option for the management of selected patients with mild hyperprolactinaemia who wish to be treated with phytotherapy. However, larger studies of high quality are needed to corroborate it.

Reproduced under CC-BY.

Topics